中金发布研报称,维持中国生物制药(6.6,0.16,2.48%)(01177)盈利预测不变和“跑赢行业”评级,当前股价交易于29.0/26.1倍2025/2026年P/E,考虑板块估值中枢上行,上调目标价26.7%到7.6港元,对应34.6/31.1倍2025/2026年P/E,隐含19.3%上行空间。7月15日晚,公司公告将以总对价9.5092亿美元收购礼新医药95.09%股权。中国生物制药已...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.